Mylan Ducks $15M Bristol-Myers Contract Suit Over HIV Drug

Law360, New York (August 12, 2013, 5:17 PM EDT) -- Mylan Inc. on Monday dodged a $15 million breach of contract suit from Bristol-Myers Squibb Co. after a New York federal judge found that an agreement between the companies didn’t bar Mylan’s sales of an HIV drug in Venezuela, although a patent infringement complaint is still possible.

The opinion from U.S. District Judge Paul A. Engelmayer turned on a highly technical reading of a contract that immunized Mylan from patent infringement liability when selling a generic version of Reyataz, or atazanavir, in India and sub-Saharan Africa....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.